logo-loader
viewPreveCeutical Medical Inc.

PreveCeutical Medical successfully develops procedures to chemically fingerprint cannabinoid extracts used to formulate Sol-gels

The advancement will enable a standardized preparation of cannabinoid extracts for infusion in its Sol-gel formulations

PreveCeutical Medical Inc. - PreveCeutical Medical Inc successfully develops standard operating procedures for the chemical fingerprinting of cannabinoids in its extracts used to formulate Sol-gels
The Sol-gel platform is a nose-to-brain delivery system developed to be water-soluble without alcohol or solvent

PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) said it has successfully developed standard operating procedures (SOPs) for the chemical fingerprinting of cannabinoids in the extracts used to formulate its proprietary Sol-gels for potential therapeutic applications.

The company said Wednesday that this advancement will enable a standardized preparation of cannabinoid extracts for infusion in its Sol-gel formulations, ensuring robust cannabinoid chemistry profiling for potential treatments to meet or exceed regulatory guidelines. 

By adopting the new SOPs, PreveCeutical said it and potential partners will be able to rapidly and consistently control the quality of the chemical composition of cannabinoids from any given cannabis/hemp strain.

READ: PreveCeutical Medical says Sol-gel cannabinoid program a success as it eyes development and commercialization

"Having established this SOPs for cannabinoid chemical fingerprinting allows us to achieve precision, consistency and content uniformity in cannabinoid Sol-gel formulations,”  PreveCeutical CEO Stephen Van Deventer said in a statement. “Furthermore, this SOPs will allow for prolonged controlled dosage release as required for specific treatments."

PreveCeutical said its objectives are to develop, commercialize, and seek other third party clinical-proven formulations to be infused with the Sol-gel platform, which is a nose-to-brain delivery system developed to be water-soluble without alcohol or solvent content to potentially treat pain, inflammation, seizures, and neurological disorders.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

 

Quick facts: PreveCeutical Medical Inc.

Price: 0.055 CAD

CSE:PREV
Market: CSE
Market Cap: $21.8 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Preveceutical announces successful preliminary evaluation of...

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...

on 15/11/19

2 min read